Category Archives: Uncategorized

This paper focuses on corneal and glaucoma outcomes among patients with Peters anomaly. Source: AAO

• Posted on: Feb 26 2020
• By: Saratoga Opthalmology
• Leave a response

The authors describe an evolutionary algorithm that designs biological machines—an approach that could one day possibly be used to safely deliver drugs or repair damaged tissue inside the human body. Source: AAO

• Posted on: Feb 25 2020
• By: Saratoga Opthalmology
• Leave a response

This study presents outcomes of patients treated with ranibizumab for branch and central retinal vein occlusion (BRVO and CRVO). Source: AAO

• Posted on: Feb 24 2020
• By: Saratoga Opthalmology
• Leave a response

This week, Chinese scientists unveil color-changing contacts that respond to ocular fluctuations, Alcon’s allergy eye drops are now available over the counter and a blue laser attack nearly blinds a highway patrol pilot. Source: AAO

• Posted on: Feb 21 2020
• By: Saratoga Opthalmology
• Leave a response

In this extension trial, investigators compared the effect of continued or discontinued use of omega-3 fatty acid supplements among participants of the DREAM study. Source: AAO

• Posted on: Feb 21 2020
• By: Saratoga Opthalmology
• Leave a response

This literature review compares the efficacy of 3 of the most commonly employed endophthalmitis prophylaxis antibiotics: cefuroxime, vancomycin and moxifloxacin. Source: AAO

• Posted on: Feb 20 2020
• By: Saratoga Opthalmology
• Leave a response

The authors described a case of a 6-year-old girl who developed bilateral optic neuritis following inactivated influenza vaccination. Source: AAO

• Posted on: Feb 19 2020
• By: Saratoga Opthalmology
• Leave a response

In a cross-sectional, population-based survey, the authors determined the association between retinal thickness and cognitive function. Source: AAO

• Posted on: Feb 18 2020
• By: Saratoga Opthalmology
• Leave a response

This week, an artificial intelligence algorithm for ROP gains breakthrough designation, a gene therapy for wet AMD shows promise and novel dexamethasone eye drops effectively treat DME. Source: AAO

• Posted on: Feb 14 2020
• By: Saratoga Opthalmology
• Leave a response

This a randomized, double-masked, placebo-controlled, phase 3 multicenter trial evaluating the insulin-like growth factor I receptor (IGF-IR) inhibitor teprotumumab for treating thyroid eye disease. Source: AAO

• Posted on: Feb 13 2020
• By: Saratoga Opthalmology
• Leave a response